Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00142779 · ClinicalTrials.gov registry record · NA

Fluoxetine to Reduce Cocaine Use in Cocaine and Opioid Addicts

A NA study, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
NA
Development phase
220
Enrollment target

NCT00142779: Completed NA study, sponsored by National Institute on Drug Abuse (NIDA).

NCT00142779 is a NA study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 220 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00142779, a NA study, has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
NA
Development phase
220 participants
Enrollment target

Study Summary

Cocaine addiction is a serious health problem with no available medical treatment for preventing relapse. Fluoxetine, a medication that is currently used to treat depression and anxiety disorders, may also be effective at diminishing cocaine use in individuals with severe cocaine addiction. This study will evaluate the effectiveness of fluoxetine at reducing cocaine use in individuals addicted to cocaine and opioids who are concurrently receiving methadone treatment.

Interventions

  • DRUG Fluoxetine

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2001-04
Est. Completion 2006-03
Phase NA

What the finished NCT00142779 record still lists

NCT00142779 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).

The record links to 0 conditions, and to 1 intervention - of which Fluoxetine is the first listed.

NCT00142779 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00142779 about?

NCT00142779 is a clinical study titled "Fluoxetine to Reduce Cocaine Use in Cocaine and Opioid Addicts". Cocaine addiction is a serious health problem with no available medical treatment for preventing relapse. Fluoxetine, a medication that is currently used to treat depression and anxiety disorders, may also be effective at diminishing cocaine use in individuals with severe cocaine addiction. This stu...

What is the current status of trial NCT00142779?

This trial is currently completed. It is a NA study. The enrollment target is 220 participants. The study started on 2001-04. Estimated completion is 2006-03.

What interventions are being tested in trial NCT00142779?

The interventions under investigation include: Fluoxetine (DRUG).

Who is sponsoring clinical trial NCT00142779?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00142779's enrollment target sits among peer trials

220 481st of 2000 higher than 1,516 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00920972 · 220 participants · Phase 1

    Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

  • NCT01851642 · 220 participants

    Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

  • NCT02582021 · 220 participants

    WISE CVD - Continuation (WISE HFpEF)

  • NCT04067830 · 220 participants · Phase 2

    Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00142779, the US trial registry maintained by the National Library of Medicine. NCT00142779 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.